Sage Therapeutics stock exits public markets after Supernus deal
Sage Therapeutics stock is no longer publicly traded following its acquisition by Supernus Pharmaceuticals for $8.50 per share on July 31, 2025. This deal integrated Sage's central nervous system pipeline, including the key asset Zurzuvae, into Supernus's neuropsychiatry business. The acquisition, valued at $561.0 million, highlighted Zurzuvae's commercial potential and its importance for Supernus's financial growth.
Supernus Pharmaceuticals, Inc. (SUPN) Stock Price, News, Quote & History
This article provides comprehensive financial data for Supernus Pharmaceuticals, Inc. (SUPN), including its current stock price, recent performance, key financial metrics, and analyst ratings. It details the company's product portfolio for CNS diseases and its development pipeline, alongside quarterly earnings and historical performance against the S&P 500.
Supernus Pharmaceuticals (SUPN) Short Interest & Short Float | Updated Sep 2026
Supernus Pharmaceuticals (SUPN) currently has a short interest of 4.99 million shares, representing 9.37% of its public float, as of September 15, 2026. This marks a 6.80% increase from the previous reporting period, indicating growing bearish sentiment among investors. The short interest ratio stands at 8.7 days to cover, suggesting it would take nearly nine trading days to cover all short positions.
Indivior Pharmaceuticals, Inc. Declares Special Cash Dividend
Indivior Pharmaceuticals, Inc. has declared a special cash dividend of $8.13 per share, contingent upon the closing of its merger with Supernus Pharmaceuticals, Inc. The dividend will be paid to shareholders of record as of October 30, 2026, and to holders of certain equity awards upon vesting, with payment expected around November 6, 2026, assuming the merger closes on November 2, 2026. This special dividend is conditional on the successful completion of the merger, which requires stockholder approvals from both companies.
Indivior Sets Special Cash Dividend at $8.13 a Share Contingent on Completion of Supernus Merger
Indivior Pharmaceuticals has announced a special cash dividend of $8.13 per share. This dividend payout is contingent upon the successful completion of its merger with Supernus Pharmaceuticals. The article also mentions recent financial updates for Indivior, including its Q2 earnings and an upgraded 2026 sales outlook.
Indivior Pharmaceuticals Declares $8.13 Special Cash Dividend Contingent on Supernus Merger Closing
Indivior Pharmaceuticals has announced a special cash dividend of $8.13 per share, contingent on the successful completion of its merger with Supernus Pharmaceuticals, expected around November 2, 2026. This dividend will be paid to shareholders and certain equity award holders as of the record date, October 30, 2026, but will not be issued if the merger fails to close. The company emphasized its commitment to addressing opioid use disorder and advised stakeholders to review the joint proxy statement/prospectus for more details.
Discipline and Rules-Based Execution in SUPN Response
This article provides an AI-driven analysis for Supernus Pharmaceuticals Inc. (NASDAQ: SUPN), indicating weak near and mid-term sentiment and a neutral long-term outlook with elevated downside risk. It details three institutional trading strategies—Position, Momentum Breakout, and Risk Hedging—along with multi-timeframe signal analysis, including support and resistance levels for various time horizons. The report highlights key findings and offers real-time trading signals and personalized alerts to registered users.
Supernus Pharmaceuticals stock hits 52-week low at 42.39 USD By Investing.com
Supernus Pharmaceuticals Inc. (SUPN) stock hit a new 52-week low of $42.39, reflecting a 5% decline over the past year and 19% in the last six months. Despite the recent stock performance, analysts remain optimistic with price targets up to $67, suggesting a potential upside of 44%. The company recently announced a merger with Indivior Pharmaceuticals, aiming to create a larger CNS-focused drugmaker.
Supernus Pharmaceuticals stock hits 52-week low at 42.39 USD
Supernus Pharmaceuticals (SUPN) stock recently hit a 52-week low of $42.39, reflecting a 5% decline over the past year and 19% in the last six months. Despite this, analysts maintain optimistic price targets, suggesting a potential 44% upside, though InvestingPro analysis indicates the stock is currently overvalued. The company recently reported mixed Q2 results and announced a merger with Indivior Pharmaceuticals, which is expected to create a larger CNS-focused drugmaker.
Supernus Pharmaceuticals to Participate in September Investor Conferences
Supernus Pharmaceuticals announced its participation in two investor conferences in September 2026: the Cantor Global Healthcare Conference on September 9th and the Wells Fargo Healthcare Conference on September 10th. Management will engage in fireside chats at both events, discussing the company's focus on developing and commercializing products for central nervous system diseases. The company encourages investors to contact conference coordinators for meeting arrangements and notes that webcast replays will be available on its website.
Supernus Pharmaceuticals to Participate in September Investor Conferences
Supernus Pharmaceuticals announced its participation in two September investor conferences: the Cantor Global Healthcare Conference and the Wells Fargo Healthcare Conference. Management will hold fireside chats at both events, and investors can access a live audio webcast and archived replays on the company's website. The company specializes in developing and commercializing products for central nervous system diseases.
Chloe Kim Teams Up with Qelbree®, the #1 Prescribed Branded
Professional snowboarder Chloe Kim is partnering with Supernus Pharmaceuticals as a compensated ambassador to discuss her journey with ADHD and her treatment plan with Qelbree. This collaboration aims to challenge misconceptions about ADHD by sharing Kim's personal experience and encouraging others to advocate for their health and discuss treatment options with their doctors. Qelbree, a non-stimulant ADHD treatment, has been widely used since its FDA approval and is currently the #1 prescribed branded non-stimulant ADHD medication.
Indivior's Supernus Merger Could Broaden Its Growth Engine in 2026
Indivior Pharmaceuticals' proposed all-stock merger with Supernus Pharmaceuticals aims to transform Indivior from an opioid use disorder-focused company into a broader central nervous system (CNS) entity with 11 marketed medicines. The deal, expected to close in Q4 2026, would diversify Indivior's revenue, generate approximately $125 million in annual cost synergies, and expand its pipeline beyond its current addiction treatments, which are heavily reliant on Sublocade. While offering significant strategic benefits, the merger's success hinges on regulatory and stockholder approvals and the effective integration of the two companies, with Indivior shareholders retaining majority ownership of the combined entity.
25,400 Shares in Supernus Pharmaceuticals, Inc. $SUPN Bought by Mystic Asset Management Inc.
Mystic Asset Management Inc. recently acquired 25,400 shares of Supernus Pharmaceuticals (NASDAQ:SUPN) valued at approximately $1.18 million. This comes as several other institutional investors also adjusted their positions in the specialty pharmaceutical company. Despite a recent earnings miss and a stock price trading down, analysts generally maintain a "Moderate Buy" rating with an average price target of $62.83.
Supernus Pharmaceuticals (SUPN) Stock Looks Reasonable On Sales While Returns Look Strong
Supernus Pharmaceuticals (SUPN) has shown strong returns over five years, with its stock price almost doubling, yet current valuations suggest it remains inexpensive. The company screens as undervalued on multiple checks, particularly on its Price/Sales (P/S) ratio compared to industry averages. The key question for investors is whether future revenue growth and product uptake will justify a re-rating closer to its peers, or if the current discount reflects concerns about margins and research spending.
Supernus Pharmaceuticals (SUPN) Stock Looks Reasonable On Sales While Returns Look Strong
Supernus Pharmaceuticals (SUPN) has shown strong returns over the past five years, with its stock almost doubling, and still appears undervalued on several measures. Despite a 16.7% return over the last year, which lags behind peers, the company's P/S multiple of 3.4x is below the industry average, suggesting potential for re-rating if revenue growth and product uptake continue. The main debate for investors is whether the current valuation gap represents mispricing or a fair reflection of execution risk.
Supernus Pharmaceuticals Reports Q2 2026 Results: Full Earnings Call Transcript
Supernus Pharmaceuticals and Indivior Pharmaceuticals are merging to form a leading CNS-focused biopharmaceutical company. The all-stock, tax-free merger is expected to create $125 million in annual cost synergies within the first year and result in a diversified portfolio of 11 medicines across addiction, ADHD, depression, and Parkinson's disease. The combined entity projects $2.2 billion in net revenue and $888 million in adjusted EBITDA, aiming to enhance financial flexibility and pursue future growth opportunities.
Rice Hall James & Associates LLC Takes $22.80 Million Position in Supernus Pharmaceuticals, Inc. $SUPN
Rice Hall James & Associates LLC has acquired a new position in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) by purchasing 490,221 shares valued at approximately $22.80 million, making it their 28th largest holding. Analyst sentiment for Supernus is a "Moderate Buy" with a consensus price target of $62.83, despite mixed recent ratings. The company recently reported quarterly revenue of $219.06 million, exceeding estimates, but posted an adjusted loss of $1.01 per share against expected earnings.
Supernus Pharmaceuticals Reports Q2 2026 Results: Full Earnings Call Transcript
Supernus Pharmaceuticals and Indivior Pharmaceuticals are merging to form a leading CNS-focused biopharmaceutical company. This tax-free merger of equals anticipates $125 million in annual cost synergies within the first year and will create a combined portfolio of 11 medicines across addiction, ADHD, depression, and Parkinson's disease. The combined entity is projected to have approximately $2.2 billion in net revenue and $888 million in adjusted EBITDA, aiming for enhanced growth opportunities and financial flexibility.
Details of Bhatt’s PSU Vesting and Tax Withholding at Supernus Pharmaceuticals
Padmanabh P. Bhatt, Senior Vice President of IP and Chief Scientific Officer at Supernus Pharmaceuticals, Inc., had 2,500 Performance Share Units (PSUs) vest on August 12, 2026. Following the vesting, 1,158 shares were withheld by the company at $46.57 per share to cover tax obligations. After these transactions, Bhatt directly owns 18,637 shares of Supernus common stock.
Supernus Pharmaceuticals (SUPN) CMO Rubin exercises PSUs and withholds shares for tax
Supernus Pharmaceuticals' Chief Medical Officer, Jonathan Rubin, exercised 750 Performance Share Units (PSUs) on August 12, 2026, converting them into 750 shares of common stock. To cover tax withholding requirements associated with this vesting, 363 shares were withheld by the company at a price of $46.57 per share. Rubin's direct holdings now include 13,979 common shares, with an additional 251 shares acquired through the company's Employee Stock Purchase Plan.
Supernus Pharmaceuticals (SUPN) CEO exercises PSUs, withholds shares for taxes
Supernus Pharmaceuticals CEO Jack A. Khattar exercised 29,849 Performance Share Units (PSUs) on August 12, 2026, converting them into common stock. Of these, 12,642 shares were withheld to cover tax obligations at a price of $46.57 per share. The transaction increased his direct common stock holdings, and he also indirectly holds 958,100 shares through the KBT Trust.
Supernus Pharmaceuticals to Announce Second Quarter 2026 Financial Results and Host Conference Call on August 4, 2026
Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN) will announce its second-quarter 2026 financial and business results on Tuesday, August 4, 2026, after market close. President and CEO Jack Khattar and Senior Vice President and CFO Tim Dec will host a conference call and webcast at 4:30 p.m. ET to discuss the results and answer questions. A live webcast and replay will be available on the company's Investor Relations website.
Supernus Pharmaceuticals, Inc. $SUPN Shares Sold by Assenagon Asset Management S.A.
Assenagon Asset Management S.A. significantly reduced its stake in Supernus Pharmaceuticals (NASDAQ:SUPN) by 86.2% in the second quarter, selling 457,443 shares and retaining 73,175 shares valued at $3.4 million. Despite this large sale, analyst sentiment for Supernus remains generally positive, with a "Moderate Buy" consensus rating and an average price target of $62.83. The stock opened at $47.87, up 2.1%, and has a market capitalization of $2.78 billion.
Indivior Pharmaceuticals (INDV) Agrees Merger That Creates New Supernus, Inc.
Indivior Pharmaceuticals (NasdaqGS: INDV) has agreed to merge with Supernus Pharmaceuticals, forming a new entity named Supernus, Inc., with shared leadership. This merger is expected to significantly reshape both companies' corporate governance and operations, especially concerning Indivior's buprenorphine-based treatments. Investors should watch the combined company's financials, particularly net debt and cash generation, post-completion, as the deal includes a new senior secured term loan and a special dividend.
Indivior Pharmaceuticals (INDV) Agrees Merger That Creates New Supernus, Inc.
Indivior Pharmaceuticals (INDV) has agreed to merge with Supernus Pharmaceuticals, forming a new entity named Supernus, Inc., with shared leadership from both companies. The merger will introduce a significant debt and a special dividend, impacting the combined company's financial structure and requiring close monitoring of its net debt and cash generation post-completion. This deal reshapes Indivior's focus beyond its buprenorphine-based treatments and integrates it into a broader neuroscience portfolio.
Indivior Pharmaceuticals (INDV) Agrees Merger That Creates New Supernus, Inc.
Indivior Pharmaceuticals (INDV) has agreed to merge with Supernus Pharmaceuticals, creating a new entity named Supernus, Inc. The combined company will feature a unified board and leadership team drawn equally from both firms. This merger aims to integrate Indivior's buprenorphine-based treatments for opioid dependence with Supernus's neuroscience portfolio, while also introducing new financial structures including a significant term loan and special dividend.
Supernus Pharmaceuticals, Inc. (SUPN) Investor Outlook: A 31% Upside Potential Amid Strong Revenue Growth
Supernus Pharmaceuticals, Inc. (SUPN) is highlighted as a prominent player in CNS therapies with a 31.19% projected upside based on analyst targets, despite recent challenges in profitability. The company boasts strong revenue growth of 32.40% and a healthy free cash flow, indicating potential for significant returns for growth-focused investors. Supernus's promising pipeline and positive analyst sentiment make it a stock worth watching in the biopharmaceutical sector.
Supernus Pharmaceuticals, Inc. (SUPN) Stock Forecasts
Argus has lowered its target price for Supernus Pharmaceuticals Inc. (SUPN) to $41.00, while the current stock price is $47.64. Supernus Pharmaceuticals specializes in developing and commercializing treatments for central nervous system diseases. Investors can access the full report with a Yahoo Finance Silver subscription.
Supernus Pharmaceuticals (NASDAQ:SUPN) Rating Increased to Strong-Buy at Zacks Research
Zacks Research has upgraded Supernus Pharmaceuticals (NASDAQ:SUPN) from a "hold" to a "strong-buy" rating. This upgrade comes despite a broader analyst consensus of "Moderate Buy" with a target price of $62.83. The company, which specializes in central nervous system therapies, also saw several institutional investors, including Millennium Management, significantly increase their holdings in Q1.
Supernus Pharmaceuticals, Inc. (SUPN) Indivior Pharmaceuticals, Inc., - M&A Call - Slideshow
This article provides access to a slide deck published by Supernus Pharmaceuticals, Inc. concerning an M&A call related to Indivior Pharmaceuticals, Inc. The content is presented by SA Transcripts, a team responsible for developing and publishing earnings call transcripts on Seeking Alpha.
Supernus and Indivior merge to create CNS mega-company with 11 approved drugs
Supernus Pharmaceuticals and Indivior Pharmaceuticals are merging in an all-stock deal to form a central nervous system-focused company with 11 marketed products and an expected annual revenue of $2.2 billion. The combined entity, which will operate as Supernus, anticipates $125 million in annual cost savings through "natural redundancies." Supernus CEO Jack Khattar will lead the new company, which aims for enhanced financial flexibility and future growth opportunities.
supernus pharmaceuticals, inc. Positive Earnings Pre-Announcements
Supernus Pharmaceuticals, Inc. announced positive earnings pre-announcements, updating its fiscal year 2026 revenue range from $840-$870 Million to $860-$890 Million. The company has been active in mergers and acquisitions, including a proposed merger with Indivior and an acquisition of Sage Therapeutics, and has seen various FDA approvals and clinical trial developments for its treatments.
Supernus Pharmaceuticals Inc (SUPN) (Q2 2026) Earnings Call Highlights: Strong Revenue Growth ...
Supernus Pharmaceuticals Inc (SUPN) reported strong revenue growth in Q2 2026, driven by key product sales and advancements in its late-stage pipeline. Despite competitive pressures and increased R&D expenses, the company reaffirmed its full-year financial guidance, projecting net revenue between $640 million and $660 million. The Q&A session highlighted discussions on product growth, pipeline progress for SPN-820, competitive strategies for Qelbree, and the company's financial health with over $300 million in cash.
supernus pharmaceuticals, inc. Positive Earnings Pre-Announcements
Supernus Pharmaceuticals, Inc. has pre-announced positive earnings, revising its fiscal year 2026 revenue guidance from an estimated $840-$870 million to $860-$890 million. This update highlights the company's financial performance and future projections. The article also provides a list of recent news related to Supernus, including mergers, quarterly results, and FDA approvals.
Supernus and Indivior merge to create scaled, CNS-focused entity
Supernus Pharmaceuticals and Indivior Pharmaceuticals are merging in an all-stock deal to form a diversified biopharmaceutical company focused on the central nervous system (CNS). The combined entity, which will operate under the name Supernus Inc. and trade on Nasdaq under 'SUPN', expects pro forma net revenue of $2.2 billion and $125 million in annual cost synergies. The merger will create a portfolio of 11 medicines for neurology, addiction, and psychiatry, with current Supernus CEO Jack Khattar leading the new company.
$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN)
Monteverde & Associates PC, a class action firm, has announced an investigation into Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) concerning its proposed sale to Indivior Pharmaceuticals, Inc. The firm is examining whether the deal, where Supernus shareholders would receive 1.5401 common shares of Indivior for each Supernus share, is fair to shareholders. Shareholders are encouraged to contact the firm for more information about the investigation.
Indivior and Supernus (SUPN) outline tax-free all-stock CNS merger of equals
Indivior Pharmaceuticals, Inc. and Supernus Pharmaceuticals, Inc. announced a definitive agreement to merge in an all-stock, tax-free transaction, creating a U.S. biopharmaceutical company focused on central nervous system (CNS) diseases. The combined entity will be headquartered in Rockville, Maryland, with Supernus CEO Jack A. Khattar serving as CEO. The merger aims to build a diversified platform with established commercial franchises, pipeline, R&D capabilities, and a strong financial profile, with closing expected in Q4 2026.
Supernus Pharmaceuticals Earnings: What To Look For From SUPN
Supernus Pharmaceuticals is set to report its Q2 earnings this Tuesday after market hours. Analysts expect the company's revenue to grow by 24.3% year-on-year, improving from the previous year's 5.6% increase. Despite Supernus Pharmaceuticals beating revenue expectations last quarter, it significantly missed EPS estimates, and its stock is currently down 5.5% over the last month.
Supernus and Indivior to Merge, Forming a New CNS-Focused Pharma Company
Supernus Pharmaceuticals and Indivior Pharmaceuticals are merging in an all-stock deal to form Supernus, Inc., a new CNS-focused pharmaceutical company. The combined entity will have a portfolio of 11 commercialized products across addiction, ADHD, depression, and Parkinson's disease, with nearly $2.2 billion in revenue. This merger is described as a "merger of equals," aiming for a broader product portfolio and enhanced financial flexibility.
CNS-focused Supernus and Indivior agree merger terms
Supernus Pharma and Indivior have agreed to an all-stock merger, forming a new company, Supernus Inc., focused on CNS diseases with combined revenues of around $2.2 billion. The deal, expected to close in Q4, will see Indivior shareholders owning 56.5% of the new company and receiving a $1 billion cash dividend. Jack Khattar, current Supernus CEO, will lead the combined entity, which anticipates $125 million in annual cost savings.
Rockville's Supernus more than tripling size through merger of equals
Rockville's Supernus Pharmaceuticals is merging with Richmond-based Indivior in a "merger of equals" transaction. The combined company will be led by current Supernus CEO Jack Khattar and is expected to generate approximately $2.2 billion in annual revenue from nearly a dozen neurological and psychiatric drugs. This merger will significantly increase Supernus's size and market presence.
Shareholder Alert: Ademi LLP investigates whether Supernus Pharmaceuticals, Inc. is obtaining a Fair Price for Public Shareholders
Ademi LLP is investigating Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN) for potential breaches of fiduciary duty related to its transaction with Indivior Pharmaceuticals. Supernus shareholders are set to receive 1.5401 common shares of Indivior for each Supernus share, resulting in Supernus stockholders owning approximately 43.5% of the combined entity. The investigation focuses on whether the Supernus board fulfilled its fiduciary duties, especially concerning potential limitations on competing bids and benefits for insiders.
Supernus Pharmaceuticals Q2 Earnings Call Highlights
Supernus Pharmaceuticals (NASDAQ:SUPN) and Indivior Pharmaceuticals announced an all-stock, tax-free merger of equals to create a CNS-focused biopharmaceutical company with an estimated $2.2 billion in pro forma revenue. The combined entity, which will retain the Supernus name and be headquartered in Rockville, Maryland, is expected to realize $125 million in annual cost synergies within the first year. The deal, anticipated to close in Q4 2026, aims to establish a CNS leader with 11 marketed medicines, including key growth products like SUBLOCADE, Qelbree, ZURZUVAE, GOCOVRI, and ONAPGO.
Supernus Pharmaceuticals and Indivior Pharmaceuticals to Merge, Creating a Diversified CNS Biopharmaceutical Leader with Significant Scale
Supernus Pharmaceuticals and Indivior Pharmaceuticals are merging in an all-stock, tax-free transaction to create a leading diversified central nervous system (CNS) biopharmaceutical company. The combined entity, to be named Supernus, Inc., is expected to have approximately $2.2 billion in annual revenues and generate $125 million in annual cost synergies. Jack Khattar will serve as President and CEO, leading a company with an enhanced financial position and a diversified portfolio of CNS medicines.
Understanding Momentum Shifts in (SUPN)
This article analyzes Supernus Pharmaceuticals Inc. (SUPN) using AI models, highlighting a neutral near-term sentiment and potential mid-term weakness. It identifies a breakdown underway, suggesting lower levels and elevated downside risk. The report provides specific institutional trading strategies, including long, breakout, and short positions, along with multi-timeframe signal analysis for support and resistance levels.
Supernus Pharmaceuticals (SUPN) awards 2,500 performance share units
Supernus Pharmaceuticals' Sr. VP of IP, CSO Padmanabh P. Bhatt, was awarded 2,500 Performance Share Units on July 29, 2026. These units, which were part of an award from February 19, 2025, vested upon the achievement of individual performance objectives set on May 3, 2025. This transaction, reported via a Form 4 SEC filing, represents equity compensation and increases Bhatt's direct holdings to 2,500 Performance Share Units.
Supernus Pharmaceuticals (NASDAQ: SUPN) CEO granted 29,849 performance share units
Supernus Pharmaceuticals CEO Jack A. Khattar was granted 29,849 Performance Share Units on July 29, 2026, which correspond to one share of common stock each. These units, awarded on February 19, 2025, vested upon the achievement of individual performance objectives established on May 3, 2025. This transaction, valued at $0.00 per unit as equity compensation, leaves the CEO holding 29,849 units from this specific award.
Supernus Pharmaceuticals, Inc. Actuals & Estimates (NASDAQ:SUPN)
This article provides an overview of Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN), including its current stock price, historical performance, analyst forecasts, and financial data. It highlights key metrics such as market capitalization, earnings per share, revenue, and EBITDA, while also offering insights into the company's employee count and upcoming earnings release. The content serves as a resource for investors to conduct their own research on SUPN stock.
Supernus Pharmaceuticals (NASDAQ: SUPN) CMO receives 750 performance share units
Jonathan Rubin, SVP and Chief Medical Officer at Supernus Pharmaceuticals (NASDAQ: SUPN), was granted 750 Performance Share Units on July 29, 2026. These units, part of an award from February 2025, vested upon the achievement of specific individual performance objectives set in May 2025. This insider transaction highlights equity-based compensation tied to performance, with the units corresponding to 750 shares of common stock.
